3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Recruiting
4
Active not recruiting
2
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Primary Myelofibrosis
9
Myeloproliferative Disorders
5
Polycythemia Vera
4
Thrombocythemia, Essential
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Breast Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thalassemia
1
Pancreatic Neoplasms
1
Other Cancer
1
Mesothelioma
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammatory Breast Neoplasms
1
Hypereosinophilic Syndrome
1
Graft vs Host Disease
1
Glioma
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Cisplatin
6
Bortezomib
6
Gemcitabine
5
venetoclax
4
elotuzumab
4
isatuximab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Letrozole
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
palbociclib
2
ixazomib
2
dexamethasone 21-phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
ruxolitinib
×
Clear all
NCT04279847
2026-04-01
LIMBER
Incyte Corporation
Phase 1
Active not recruiting
140 enrolled
NCT06768476
2026-01-16
AML
University of Pennsylvania
Phase 1
Active not recruiting
12 enrolled